IP Library Granted Patent US 8,283,350
Granted Patent B2
US 8,283,350 · App. 12/460,970 · Granted Oct 9, 2012

Compositions and methods for reducing capillary permeability

Assignee: Alpha Synergy Development, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,283,350
App. No.
12/460,970
Granted
Oct 9, 2012
Kind
B2
Abstract

The invention generally relates to compositions and methods for reducing capillary permeability. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.

Claims (5)

1. A method of reducing capillary permeability in a pulmonary condition associated with swollen nasal turbinates comprising administering to a patient in need thereof a composition consisting essentially of brimonidine, wherein pH of said composition is between about 3.5 and about 6.5, wherein said brimonidine concentration is from between about 0.001% to about 0.025% weight by volume, and wherein said composition is formulated as an aerosolized composition, and wherein the composition is administered into a nasal airway of the patient.

2. The method of claim 1 wherein spread of pathogens associated with said pulmonary condition is reduced.

3. The method of claim 1 , further comprising reducing or alleviating an allergic or an inflammatory condition of the respiratory tract of said patient.

4. A method of reducing capillary permeability in a pulmonary condition associated with swollen nasal turbinates comprising administering to a patient in need thereof a composition consisting essentially of brimonidine, wherein pH of said composition is between about 5.0 and about 6.5, wherein said brimonidine concentration is from between about 0.001% to about 0.025% weight by volume, and wherein said composition is formulated as an aerosolized composition, and wherein the composition is administered into a nasal airway of the patient.

5. The method of claim 1 , wherein said patient has a nasal congestion.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 19, 2012
From: ALPHA SYNERGY DEVELOPMENT, INC.
To: EYE THERAPIES LLC
Reel/Frame 029321/0739 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2009
From: HORN, GERALD
To: ALPHA SYNERGY DEVELOPMENT, INC.
Reel/Frame 023059/0846 →
Continuity (5)
Provisional Application 61137714 · Aug 1, 2008
Provisional Application 61192777 · Sep 22, 2008
Provisional Application 61203120 · Dec 18, 2008
Provisional Application 61207481 · Feb 12, 2009
Related Publication 20100028267A1 · Feb 4, 2010